GENFIT: June 30, 2020 Annual Shareholders Meeting results
30 Juin 2020 - 10:05PM
GENFIT: June 30, 2020 Annual Shareholders Meeting results
Lille (France); Cambridge (Massachusetts,
United States) — June 30, 2020 — GENFIT (Nasdaq and
Euronext: GNFT), a late-stage biopharmaceutical company
dedicated to improving the lives of patients with metabolic and
chronic liver diseases, today announced the results of the voting
by shareholders at the Ordinary Shareholders’ Meeting which took
place on June 30, 2020 at the Company’s headquarters.
All of the resolutions were adopted by a large
majority of the votes cast, in accordance with the Board of
Directors’ recommendations. 6,840,148 shares participated out of a
total of 38,812,919 shares with voting rights, representing a
quorum of 17.62%.
The details on voting resolution by resolution
are available on the Company’s website in the investor’s room at
https://ir.genfit.com/financial-information/shareholders-meeting.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC. As part of GENFIT’s
comprehensive approach to clinical management of patients with
NASH, GENFIT is also developing a new, non-invasive blood-based
diagnostic test, NIS4, which, if approved, could enable easier
identification of patients with NASH. With facilities in Lille and
Paris, France, and Cambridge, MA, USA, the Company has
approximately 200 employees. GENFIT is a publicly traded company
listed on the Nasdaq Global Select Market and in compartment B of
Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
- GENFIT: June 30, 2020 Annual Shareholders Meeting results